| P2093 | author name string | J. Scott Roberts | |
| | Sarah M. Tersegno | |
| P2860 | cites work | Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study | Q48336337 |
| | On the discovery of the genetic association of Apolipoprotein E genotypes and common late-onset Alzheimer disease. | Q48445040 |
| | Public attitudes about genetic testing for Alzheimer's disease | Q48664461 |
| | Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab | Q48882820 |
| | Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease | Q49141542 |
| | Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. | Q50747108 |
| | Forecasting the global burden of Alzheimer’s disease | Q22252403 |
| | Genetic risk and behavioural change | Q24525204 |
| | Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease | Q24612662 |
| | 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment | Q24648319 |
| | Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons | Q24652687 |
| | Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association | Q24683646 |
| | A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 |
| | Mild cognitive impairment: clinical characterization and outcome | Q28140626 |
| | Influence of education and occupation on the incidence of Alzheimer's disease | Q28251102 |
| | Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium | Q28252389 |
| | Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database | Q28280965 |
| | Impact of APOE in mild cognitive impairment | Q28294566 |
| | Influence of education and occupation on the incidence of Alzheimer's disease | Q29306276 |
| | Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade | Q29614407 |
| | Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease | Q29614881 |
| | Mild cognitive impairment as a diagnostic entity | Q29619568 |
| | A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. | Q30446969 |
| | How can we help people make sense of medical data? | Q30583421 |
| | Core candidate neurochemical and imaging biomarkers of Alzheimer's disease | Q31162752 |
| | Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review | Q33205241 |
| | Cognitive reserve | Q33452282 |
| | Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease | Q33572491 |
| | Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization | Q33601338 |
| | The neuropathology of probable Alzheimer disease and mild cognitive impairment | Q33616561 |
| | The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics | Q33650976 |
| | The new genetics. Psychological responses to genetic testing | Q33789196 |
| | Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum | Q33870467 |
| | An active and socially integrated lifestyle in late life might protect against dementia | Q33978519 |
| | Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial | Q34049921 |
| | Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members | Q34053221 |
| | Physical exercise, aging, and mild cognitive impairment: a population-based study | Q34058821 |
| | Psychological impact of genetic testing for Huntington's disease: an update of the literature | Q34060489 |
| | Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. | Q50798207 |
| | The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. | Q50866744 |
| | Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? | Q51034742 |
| | A survey of attitudes of clinicians towards the diagnosis and treatment of mild cognitive impairment in Australia and New Zealand. | Q51902565 |
| | Effects of attributing serious mental illnesses to genetic causes on orientations to treatment. | Q51920543 |
| | Neuropsychological detection and characterization of preclinical Alzheimer's disease. | Q52053210 |
| | Risk of dementia among white and African American relatives of patients with Alzheimer disease. | Q53246105 |
| | Dementia and Alzheimer disease incidence: a prospective cohort study. | Q53251602 |
| | Proposed international guidelines on ethical issues in medical genetics and genetic services (part I). | Q53274862 |
| | Genetics. Once shunned, test for Alzheimer's risk headed to market. | Q53292453 |
| | Issues in molecular genetic testing of individuals with suspected early-onset familial Alzheimer's disease. | Q53315932 |
| | Informing study participants of research results: an ethical imperative. | Q53368757 |
| | Alzheimer's drug pipeline is robust, and usage is quickly expanding. | Q53402221 |
| | Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. | Q55041761 |
| | ASHG Statement* on Direct-to-Consumer Genetic Testing in the United States | Q57197774 |
| | Statement on Use of Apolipoprotein E Testing for Alzheimer Disease | Q57319084 |
| | Causal attributions for raised cholesterol and perceptions of effective risk-reduction: Self-regulation strategies for an increased risk of coronary heart disease | Q57745394 |
| | Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease | Q57782086 |
| | Biomarkers for Alzheimer’s disease | Q58186173 |
| | Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial | Q60697564 |
| | Projecting individualized probabilities of developing breast cancer for white females who are being examined annually | Q69396132 |
| | Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group | Q71002608 |
| | Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease | Q71516143 |
| | Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons | Q73859381 |
| | Genomic medicine: who will practice it? A call to open arms | Q77455194 |
| | What length of hospice use maximizes reduction in medical expenditures near death in the US Medicare program? | Q80546288 |
| | The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis | Q80828389 |
| | Genomic profiles for disease risk: predictive or premature? | Q80893894 |
| | The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone | Q82183404 |
| | Leisure activities and the risk of dementia in the elderly: results from the Three-City Study | Q84559008 |
| | Social engagement and cognitive function in old age. | Q37380016 |
| | Relationships between biomarkers in aging and dementia | Q37393992 |
| | Disclosure of APOE genotype for risk of Alzheimer's disease | Q37423417 |
| | Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. | Q37493113 |
| | Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies | Q37527706 |
| | Systematic review of health behavioral risks and cognitive health in older adults | Q37626139 |
| | Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. | Q37703299 |
| | Reaction to a dementia diagnosis in individuals with Alzheimer's disease and mild cognitive impairment | Q39325063 |
| | 2009 Alzheimer's disease facts and figures | Q39981246 |
| | Projecting individualized absolute invasive breast cancer risk in African American women | Q40149673 |
| | Making sense of mild cognitive impairment: a qualitative exploration of the patient's experience | Q40260023 |
| | Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research | Q40389106 |
| | Emotional responses to APO E genotype disclosure for Alzheimer disease | Q40413758 |
| | Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial | Q40494480 |
| | Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives | Q40770742 |
| | Early detection of Alzheimer disease: methods, markers, and misgivings | Q40911003 |
| | The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective | Q41366395 |
| | Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? | Q44411562 |
| | Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease | Q44470398 |
| | Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older | Q45012815 |
| | The incidence of dementia: a meta-analysis | Q45174488 |
| | Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk | Q45292147 |
| | Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test | Q45292803 |
| | Uptake of presymptomatic predictive testing for Huntington's disease | Q45296107 |
| | Predictive testing for Huntington's disease: the calm after the storm | Q45301909 |
| | CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. | Q45923691 |
| | Moderate alcohol consumption, apolipoprotein E, and neuroprotection | Q46052041 |
| | An agenda for personalized medicine | Q46071434 |
| | The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics | Q46544681 |
| | APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease | Q47714152 |
| | Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study | Q47790444 |
| | Genetic testing and Alzheimer disease: has the time come? Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics & Society | Q47852781 |
| | 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration | Q48210315 |
| | "I know what you told me, but this is what I think:" perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate | Q34065940 |
| | Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib | Q34077849 |
| | Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia | Q34101831 |
| | A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease | Q34159318 |
| | Trinucleotide repeat length instability and age of onset in Huntington's disease | Q34357407 |
| | Vitamin E and donepezil for the treatment of mild cognitive impairment | Q34411313 |
| | Human genetics on the web. | Q34433473 |
| | Mixed dementia: emerging concepts and therapeutic implications | Q34553430 |
| | Disclosing individual genetic results to research participants | Q34579296 |
| | Prevalence of dementia in the United States: the aging, demographics, and memory study. | Q34584456 |
| | Genetics of Alzheimer's disease: a centennial review | Q34656812 |
| | Promising strategies for the prevention of dementia | Q34659276 |
| | Effects of aerobic exercise on mild cognitive impairment: a controlled trial | Q34666688 |
| | Mild cognitive impairment: ten years later | Q34847370 |
| | Alcohol drinking, cognitive functions in older age, predementia, and dementia syndromes | Q34984770 |
| | International studies in dementia with particular emphasis on populations of African origin | Q35538341 |
| | Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior | Q35567406 |
| | Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). | Q35781558 |
| | Simple tools for understanding risks: from innumeracy to insight | Q36037510 |
| | CSF biomarkers for mild cognitive impairment and early Alzheimer's disease | Q36095322 |
| | Dementia update 2005. | Q36155128 |
| | Defining and redefining the scope and goals of genetic counseling | Q36551552 |
| | Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction | Q36634289 |
| | Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study | Q36790111 |
| | Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience | Q36790121 |
| | Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations | Q36943299 |
| | A systematic review of perceived risks, psychological and behavioral impacts of genetic testing | Q37057762 |
| | Anchoring-and-adjustment bias in communication of disease risk | Q37157787 |
| | The Genetic Information Nondiscrimination Act--a half-step toward risk sharing | Q37225067 |
| | Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects | Q37227424 |
| | Predicting risk of dementia in older adults: The late-life dementia risk index | Q37274596 |
| | The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety | Q37299239 |
| | Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study | Q37310717 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 501-517 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | Future Neurology | Q15760623 |
| P1476 | title | Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions | |
| | Estimating and disclosing the risk of developing Alzheimer‘s disease: challenges, controversies and future directions | |
| P478 | volume | 5 | |